HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amazon’s VMS Policy Mirrors US FDA Rules But May Reflect Stronger Industry Compliance

Executive Summary

Amazon’s requirements reach to guaranteeing ingredients are compliant with FDA regulations. While the agency, for the most part, isn’t preventing sales of supplements containing ingredients that have not been notified as NDIs with proof of reasonable expectation of safety, Amazon could ask marketers for the information.

You may also be interested in...



Amazon Response About Drug-Spiked Supplements ‘Not Sufficient To Protect Public’ – FDA

“Amazon has taken some action when alerted by the FDA about sales” of violative supplements, but FDA "found that other such products continue to be offered for sale” by the firm through its Fulfillment by Amazon service, according to untitled letter.

Amazon’s Dietary Supplement Quality Control Standards Well-Intended But Short-Sighted

Amazon’s quality control requirements for supplements shouldn’t rely on third-party certification for finished-product specifications but on FDA’s GMPs, says consultant Tara Couch. Attorneys Robert Durkin and Kevin Bell say companies are gaming the system by submitting fraudulent CoAs.

US Supplement Market Regulation: Depression Claim, Undisclosed Drug, COVID Tincture

FDA warns 10 businesses they’re marketing unapproved and misbranded drugs by making claims for supplements to treat depression. Supplement also found with one of, if not the most common violations in the US supplement market: it contained an undisclosed ED drug.

Topics

UsernamePublicRestriction

Register

RS150878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel